Live Breaking News & Updates on Merrimack Pharmaceuticals Daily

Stay updated with breaking news from Merrimack pharmaceuticals daily. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Increases Dividend to $15.10 Per Share

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK – Get Free Report) announced a dividend on Thursday, May 16th, investing.com reports. Shareholders of record on Tuesday, May 21st will be paid a dividend of 15.10 per share by the biopharmaceutical company on Friday, May 17th. This represents a yield of 99.87%. The ex-dividend date is Monday, May 20th. This […] ....

United States , United Kingdom , News Ratings For Merrimack Pharmaceuticals Daily , Merrimack Pharmaceuticals Company Profile , Merrimack Pharmaceuticals Stock Performance , Merrimack Pharmaceuticals , Merrimack Pharmaceuticals Inc , Get Free Report , Merrimack Pharmaceuticals Daily ,

Merrimack Pharmaceuticals (NASDAQ:MACK) Cut to "Sell" at StockNews.com

StockNews.com cut shares of Merrimack Pharmaceuticals (NASDAQ:MACK – Free Report) from a hold rating to a sell rating in a research report released on Monday morning. Merrimack Pharmaceuticals Trading Up 0.1 % Merrimack Pharmaceuticals stock opened at $15.13 on Monday. The firm has a market capitalization of $219.84 million, a P/E ratio of -189.13 and […] ....

United States , United Kingdom , Wittenberg Investment Management Inc , Kennedy Capital Management , Merrimack Pharmaceuticals Trading , Hedge Funds Weigh In On Merrimack Pharmaceuticals , Merrimack Pharmaceuticals Inc , Aristides Capital , Merrimack Pharmaceuticals Increases Dividend , Merrimack Pharmaceuticals , News Ratings For Merrimack Pharmaceuticals Daily , Free Report , Get Free Report , Financial Markets , Capital Management , Investment Management , Merrimack Pharmaceuticals Daily ,

Merrimack Pharmaceuticals (NASDAQ:MACK) Shares Pass Above 200-Day Moving Average of $12.55

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK – Get Free Report) passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $12.55 and traded as high as $13.47. Merrimack Pharmaceuticals shares last traded at $13.44, with a volume of 29,917 shares traded. Analysts Set New Price Targets Separately, StockNews.com […] ....

United States , United Kingdom , Eric Andersen , Merrimack Pharmaceuticals Trading Down , News Ratings For Merrimack Pharmaceuticals Daily , Merrimack Pharmaceuticals Inc , Securities Exchange Commission , Merrimack Pharmaceuticals , Citigroup Inc , Get Free Report , Pharmaceuticals Trading Down , Director Eric Andersen , Exchange Commission , California State Teachers Retirement System , Merrimack Pharmaceuticals Daily , Nasdaq Mack ,

Merrimack Pharmaceuticals (NASDAQ:MACK) versus Cellectar Biosciences (NASDAQ:CLRB) Financial Contrast

Merrimack Pharmaceuticals (NASDAQ:MACK – Get Free Report) and Cellectar Biosciences (NASDAQ:CLRB – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, analyst recommendations and institutional ownership. Earnings & Valuation This table compares Merrimack […] ....

Florham Park , New Jersey , United States , United Kingdom , Cellectar Biosciences , Cellectar Bioscience , Merrimack Pharmaceuticals Inc , Merrimack Pharmaceuticals , News Ratings For Merrimack Pharmaceuticals Daily , Cellectar Biosciences Inc , Get Free Report , Given Cellectar Bioscience , Orano Med , Merrimack Pharmaceuticals Daily , Nasdaq Mack , Stock Comparison , Stock Analysis ,